Amotiv Limited
Knight Therapeutics Inc. develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting;… Read more
Amotiv Limited (AOV) - Net Assets
Latest net assets as of September 2025: CA$766.79 Million CAD
Based on the latest financial reports, Amotiv Limited (AOV) has net assets worth CA$766.79 Million CAD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CA$1.05 Billion) and total liabilities (CA$281.78 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CA$766.79 Million |
| % of Total Assets | 73.13% |
| Annual Growth Rate | 5.2% |
| 5-Year Change | -10.28% |
| 10-Year Change | 23.84% |
| Growth Volatility | 19.45 |
Amotiv Limited - Net Assets Trend (2014–2024)
This chart illustrates how Amotiv Limited's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Amotiv Limited (2014–2024)
The table below shows the annual net assets of Amotiv Limited from 2014 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CA$795.11 Million | +6.46% |
| 2023-12-31 | CA$746.87 Million | -9.56% |
| 2022-12-31 | CA$825.86 Million | -1.92% |
| 2021-12-31 | CA$842.02 Million | -4.99% |
| 2020-12-31 | CA$886.24 Million | -3.15% |
| 2019-12-31 | CA$915.11 Million | -11.16% |
| 2018-12-31 | CA$1.03 Billion | +3.92% |
| 2017-12-31 | CA$991.21 Million | +1.17% |
| 2016-12-31 | CA$979.72 Million | +52.59% |
| 2015-12-31 | CA$642.06 Million | +34.04% |
| 2014-12-31 | CA$478.99 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Amotiv Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 15491100000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CA$154.91 Million | 19.48% |
| Common Stock | CA$534.27 Million | 67.19% |
| Other Components | CA$105.93 Million | 13.32% |
| Total Equity | CA$795.11 Million | 100.00% |
Amotiv Limited Competitors by Market Cap
The table below lists competitors of Amotiv Limited ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Assystem S.A.
PA:ASY
|
$227.55 Million |
|
CASIN Real Estate Development Group Co Ltd
SHE:000838
|
$227.56 Million |
|
Partron Co. Ltd
KQ:091700
|
$227.61 Million |
|
Ningbo Zhongbai Co Ltd
SHG:600857
|
$227.63 Million |
|
Agesa Hayat ve Emeklilik AS
IS:AGESA
|
$227.49 Million |
|
CyberTAN Technology Inc
TW:3062
|
$227.43 Million |
|
SUNAC SERVIC.HLDGS HD-01
F:65D
|
$227.42 Million |
|
Daou Data Corp
KQ:032190
|
$227.30 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Amotiv Limited's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 746,871,000 to 795,105,000, a change of 48,234,000 (6.5%).
- Net income of 4,332,000 contributed positively to equity growth.
- Share repurchases of 8,290,000 reduced equity.
- Other factors increased equity by 52,192,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CA$4.33 Million | +0.54% |
| Share Repurchases | CA$8.29 Million | -1.04% |
| Other Changes | CA$52.19 Million | +6.56% |
| Total Change | CA$- | 6.46% |
Book Value vs Market Value Analysis
This analysis compares Amotiv Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.77x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 352368653.40x to 0.77x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2013-12-31 | CA$0.00 | CA$6.15 | x |
| 2014-12-31 | CA$8.36 | CA$6.15 | x |
| 2015-12-31 | CA$6.65 | CA$6.15 | x |
| 2016-12-31 | CA$8.08 | CA$6.15 | x |
| 2017-12-31 | CA$6.91 | CA$6.15 | x |
| 2018-12-31 | CA$7.19 | CA$6.15 | x |
| 2019-12-31 | CA$5.79 | CA$6.15 | x |
| 2020-12-31 | CA$6.71 | CA$6.15 | x |
| 2021-12-31 | CA$6.76 | CA$6.15 | x |
| 2022-12-31 | CA$7.19 | CA$6.15 | x |
| 2023-12-31 | CA$7.38 | CA$6.15 | x |
| 2024-12-31 | CA$7.95 | CA$6.15 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Amotiv Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.54%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 1.17%
- • Asset Turnover: 0.39x
- • Equity Multiplier: 1.21x
- Recent ROE (0.54%) is below the historical average (3.59%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | 26.28% | 34451.40% | 0.00x | 1.02x | CA$77.96 Million |
| 2015 | 5.32% | 3294.79% | 0.00x | 1.01x | CA$-30.04 Million |
| 2016 | 1.89% | 312.46% | 0.01x | 1.01x | CA$-79.41 Million |
| 2017 | 1.74% | 199.72% | 0.01x | 1.01x | CA$-81.88 Million |
| 2018 | 2.34% | 192.63% | 0.01x | 1.02x | CA$-78.92 Million |
| 2019 | 1.79% | 30.59% | 0.04x | 1.61x | CA$-66.56 Million |
| 2020 | 3.58% | 15.92% | 0.19x | 1.17x | CA$-56.86 Million |
| 2021 | 1.86% | 6.44% | 0.25x | 1.18x | CA$-68.53 Million |
| 2022 | -3.62% | -10.18% | 0.28x | 1.28x | CA$-112.48 Million |
| 2023 | -2.25% | -5.13% | 0.35x | 1.27x | CA$-91.52 Million |
| 2024 | 0.54% | 1.17% | 0.39x | 1.21x | CA$-75.18 Million |
Industry Comparison
This section compares Amotiv Limited's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $42,647,474
- Average return on equity (ROE) among peers: -337.32%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Amotiv Limited (AOV) | CA$766.79 Million | 26.28% | 0.37x | $227.52 Million |
| Cannabist Company Holdings Inc (CBST) | $-986.97K | 0.00% | 0.00x | $11.81 Million |
| DRI Healthcare Trust (DHT-U) | $372.34 Million | 3.11% | 0.70x | $450.44 Million |
| GenixPharmaceucticals Corporation (GENX) | $4.01 Million | -41.17% | 0.19x | $451.93K |
| Simply Solventless Concentrates Ltd. (HASH) | $1.78 Million | -130.46% | 0.98x | $2.81 Million |
| The Hempshire Group Corp. (HMPG) | $-835.46K | 0.00% | 0.00x | $515.15K |
| LSL Pharma Group Inc. (LSL) | $7.48 Million | 1.18% | 2.18x | $24.09 Million |
| Good Shroom Co Inc (MUSH) | $242.01K | -170.37% | 3.22x | $2.78 Million |
| Navasota Resources Inc. (NAV) | $3.47K | -2698.16% | 31.31x | $132.92K |
| Verano Holdings Corp Ordinary Shares - Class A (Sub Voting) (VRNO) | $-216.50K | 0.00% | 0.00x | $303.72 Million |